# Deep Brain Stimulation for Movement Disorders

## Overview

Deep brain stimulation involves the implantation of electrodes into specific deep brain nuclei to modulate neural circuit activity with electrical stimulation. FDA-approved indications include Parkinson disease, essential tremor, dystonia, obsessive-compulsive disorder under humanitarian device exemption, and epilepsy targeting the anterior nucleus of the thalamus. Investigational indications continue to expand and include Tourette syndrome, depression, Alzheimer disease, and addiction. DBS does not cure the underlying disease but provides symptomatic relief by modulating pathological circuit activity. A key advantage over ablative procedures is that it is both reversible and adjustable.

## Mechanism of Action

The mechanism of DBS is not fully understood but is best conceptualized as "jamming" of pathological oscillatory activity within basal ganglia-thalamocortical circuits. High-frequency stimulation at 130 to 185 Hz creates a functional effect similar to a lesion but with greater complexity. Proposed mechanisms include inhibition of cell bodies around the electrode, activation of axons passing near the electrode, disruption of pathological beta-band oscillations in the 13 to 30 Hz range in Parkinson disease, regularization of firing patterns in the basal ganglia, and antidromic activation of cortical inputs. The volume of tissue activated depends on electrode configuration, amplitude, pulse width, and frequency.

## Targets for Movement Disorders

### Subthalamic Nucleus

The STN is the primary target for Parkinson disease. It is a small biconvex nucleus measuring approximately 6 by 4 by 5 millimeters, located anterior to the red nucleus and lateral to the hypothalamus. The dorsolateral sensorimotor region is the optimal stimulation target. Advantages of STN stimulation include the ability to significantly reduce dopaminergic medications by 30 to 60 percent, improvement in all cardinal motor symptoms, and the small size that allows precise targeting. Disadvantages include a narrow therapeutic window where stimulation of adjacent structures can cause speech difficulty, mood changes, eyelid opening apraxia, or muscle contractions. Cognitive and behavioral side effects including impulsivity and mood changes are documented. Approximate MRI-based coordinates are 12 millimeters lateral, 2 millimeters posterior, and 4 millimeters inferior to the mid-commissural point.

### Globus Pallidus Internus

The GPi serves as an alternative PD target and the primary target for dystonia. It is a larger nucleus than the STN, with the dorsolateral motor region targeted for PD and the posteroventral region for dystonia. For PD, advantages include a wider therapeutic window, fewer psychiatric side effects, and better suitability for patients with psychiatric comorbidities or cognitive concerns. The disadvantage for PD is that it does not allow medication reduction unlike STN. For dystonia, GPi stimulation produces excellent outcomes, though the response may be delayed by weeks to months. The best results are seen in DYT1 generalized dystonia with 60 to 80 percent improvement. Approximate coordinates are 20 millimeters lateral, 2 millimeters anterior, and 4 millimeters inferior to the mid-commissural point.

### Ventral Intermediate Nucleus of the Thalamus

The VIM is the primary target for essential tremor. It is a relay nucleus in the cerebellar-thalamocortical circuit. Tremor suppression is excellent at 80 to 90 percent improvement. However, VIM stimulation does not improve bradykinesia or rigidity and is therefore not used for PD motor symptoms other than tremor-dominant disease. Approximate coordinates are 14 to 15 millimeters lateral to the midline at the level of the AC-PC line.

| Target | Primary Indication | Coordinates (from MCP) | Key Advantage | Key Disadvantage |
|--------|-------------------|----------------------|---------------|------------------|
| STN | Parkinson disease | 12 lat, 2 post, 4 inf | Allows 30-60% medication reduction | Narrow therapeutic window, mood effects |
| GPi | Dystonia; PD alternative | 20 lat, 2 ant, 4 inf | Wider therapeutic window, fewer psych effects | No medication reduction for PD |
| VIM | Essential tremor | 14-15 lat at AC-PC | 80-90% tremor suppression | Does not improve bradykinesia/rigidity |

### Posterior Subthalamic Area / Caudal Zona Incerta

This is an emerging target for both essential tremor and PD tremor. Some evidence suggests superior tremor control compared to VIM, but it remains less well-established and is the subject of ongoing research.

## Patient Selection

### Parkinson Disease

The ideal candidate has idiopathic Parkinson disease rather than a parkinsonism-plus syndrome, demonstrates a clear levodopa response with greater than 30 percent improvement on UPDRS-III during the "on" medication state, has disabling motor fluctuations or dyskinesias despite optimized medications, maintains adequate cognition with a MoCA above 22 to 24 and no dementia, has no significant untreated psychiatric disease, and is traditionally under 70 years though physiological age matters more than chronological age.

Contraindications include parkinsonism-plus syndromes such as multiple system atrophy, progressive supranuclear palsy, and corticobasal syndrome, which do not respond to DBS. Dementia is a contraindication because DBS worsens cognitive function in demented patients. Active untreated psychiatric illness and unrealistic expectations also preclude surgery. The key principle is that DBS improves levodopa-responsive symptoms; symptoms that do not respond to levodopa will not respond to DBS, with the exception of tremor, which may respond even when levodopa-resistant.

### Essential Tremor

The ideal candidate has disabling tremor refractory to medications including propranolol and primidone, with action or postural tremor affecting daily function such as writing, eating, and drinking, and no significant cognitive impairment. VIM DBS is performed bilaterally for bilateral tremor, though bilateral VIM DBS increases dysarthria risk. MRI-guided focused ultrasound thalamotomy is an FDA-approved alternative that is ablative, unilateral, requires no implant, and is growing in popularity.

### Dystonia

The best results occur in primary generalized dystonia, especially DYT1/TOR1A mutation-positive cases. Good results are achieved in cervical and segmental dystonia. Variable results are seen in secondary dystonia from stroke or cerebral palsy, while tardive dystonia responds well. The GPi is the target, and the response may take weeks to months, unlike tremor suppression which is immediate.

## Surgical Technique

### Preoperative Planning

High-resolution MRI at 3 Tesla is preferred, including T1, T2, FLAIR, and susceptibility sequences. Direct targeting identifies the target nucleus on MRI, with the STN being visible on T2 and SWI sequences. Indirect targeting calculates coordinates relative to the AC-PC line using a stereotactic atlas. The MRI is merged with the stereotactic frame system or frameless platform such as the Nexframe or ROSA robot.

### Awake Procedure

The traditional approach uses local anesthesia with the patient awake for microelectrode recording and clinical testing. Frame-based stereotaxy guides electrode placement. Microelectrode recording identifies the target based on neuronal firing patterns: the STN demonstrates high-frequency irregular burst firing with cells responding to passive limb movement, the GPi shows high-frequency tonic discharge, and VIM cells fire in synchrony with tremor. MER refines targeting and multiple tracks may be performed. Macrostimulation through the DBS electrode then assesses benefit and side effects, monitoring tremor suppression and rigidity improvement while watching for paresthesias, muscle contractions, speech changes, or eye deviation. The permanent electrode is implanted and secured at the burr hole.

### Asleep DBS

This approach uses general anesthesia without MER or clinical testing. Electrode placement is guided by intraoperative imaging with MRI or CT, and position is verified before leaving the operating room. Growing evidence suggests equivalent outcomes to awake MER-guided placement. Advantages include patient comfort, absence of movement artifact, and shorter procedure time. The disadvantage is the inability to perform real-time clinical testing.

### Implantable Pulse Generator

The IPG is placed in a subclavicular pocket like a cardiac pacemaker, usually on the same day or staged within one to two weeks. It connects to the electrode via a tunneled extension cable. Battery life is 3 to 5 years for non-rechargeable and 10 to 25 years for rechargeable devices. Programming begins 2 to 4 weeks after surgery to allow the microlesion effect to resolve.

## Programming

### Parameters

Amplitude, measured in voltage or milliamperes, controls the volume of tissue activated and typically ranges from 1 to 5 volts or milliamperes. Pulse width defines the duration of each stimulus pulse at 60 to 120 microseconds. Frequency sets the stimulation rate at 130 to 185 Hz for most applications. Contact selection determines which electrode contacts are activated in monopolar or bipolar configurations. Directional leads with segmented contacts allow steering of the stimulation field to maximize benefit and minimize side effects.

### Programming Strategy

An initial monopolar survey tests each contact individually to determine the therapeutic window between the threshold for benefit and the threshold for side effects. The contact with the best therapeutic window is selected, and amplitude is gradually increased to optimize motor benefit. Multiple programming sessions over weeks to months are typical, with medication adjustment in parallel, especially for PD where levodopa is reduced after STN DBS.

## Complications

### Surgical

Intracranial hemorrhage occurs in 1 to 2 percent per lead, with symptomatic hemorrhage in less than 1 percent, and remains the most feared complication. Infection affects 3 to 5 percent and may require device explantation. Lead malposition is reduced with image verification. Seizure occurs in less than 1 percent. Air embolism from the semi-sitting position is rare with modern techniques. Hardware erosion or fracture occurs in 1 to 3 percent per year.

### Stimulation-Related

Dysarthria is particularly common with bilateral STN or VIM DBS. Paresthesias result from stimulation of adjacent sensory structures. Muscle contractions occur from internal capsule stimulation. Eyelid opening apraxia can develop with STN DBS. Mood and behavioral changes including depression, mania, and impulsivity are documented with STN DBS. Gait and balance worsening can occur with both STN and GPi. Weight gain occurs with STN DBS, partly from medication reduction.

### Long-Term

Disease progression continues despite DBS, as Parkinson disease advances regardless of stimulation. Stimulation tolerance may require parameter adjustments. Battery depletion requires generator replacement. Newer DBS systems are MRI-conditional with specific SAR and coil restrictions rather than MRI-safe.

## Key Trials

The EARLYSTIM trial in 2013 demonstrated that STN-DBS was superior to best medical therapy in early motor complications of PD, establishing that DBS need not be reserved as a "last resort." The VA Cooperative Study in 2009 showed that DBS of either STN or GPi was superior to medical therapy for advanced PD, with no significant difference between the two targets at two years for motor outcomes. The INTREPID trial in 2020 confirmed VIM DBS superiority over sham stimulation for essential tremor.

<image>Axial T2-weighted MRI at the level of the subthalamic nucleus (STN), demonstrating bilateral DBS electrodes with their tips positioned within the dorsolateral STN, visible as hypointense signal artifacts within the hyperintense STN on T2 imaging, with the red nucleus visible medially and the substantia nigra posteriorly</image>

<image>Postoperative CT scan merged with preoperative MRI showing the trajectory of a DBS electrode from a frontal burr hole through the brain parenchyma to its target in the subthalamic nucleus, with the four electrode contacts visible at the tip of the lead within the planned target volume</image>

<image>Photograph of a complete deep brain stimulation system laid out, showing the quadripolar DBS electrode lead, the extension cable, and the implantable pulse generator (IPG), demonstrating how the components connect from the intracranial electrode through the subcutaneous extension cable to the subclavicular IPG</image>

## Clinical Pearls

DBS for Parkinson disease improves levodopa-responsive symptoms; if a symptom does not improve with levodopa (with the exception of tremor), it will not improve with DBS, making the levodopa challenge test an essential predictor of outcome. Parkinsonism-plus syndromes including MSA, PSP, and CBS are contraindications to DBS; accurate diagnosis before surgery is essential, and DaTscan with clinical reassessment should be considered when the diagnosis is uncertain. When choosing between STN and GPi for PD, STN allows medication reduction and is preferred in most centers, while GPi offers a safer profile in patients with cognitive or psychiatric vulnerability. Bilateral VIM DBS for essential tremor carries a significant dysarthria risk of 20 to 30 percent; consider unilateral DBS for the dominant hand combined with MRgFUS thalamotomy for the contralateral side. DBS for dystonia has a delayed onset of benefit spanning weeks to months, and appropriate expectations must be set with patients and families. Rechargeable IPGs are increasingly preferred to avoid frequent battery replacement surgeries but require patient compliance with regular recharging. DBS electrodes are MRI-conditional rather than MRI-safe, and strict adherence to manufacturer guidelines for MRI scanning is essential to avoid tissue heating and injury.

## References
1. Limousin P et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998;339(16):1105-1111.
2. Weaver FM et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease. JAMA. 2009;301(1):63-73.
3. Schuepbach WM et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013;368(7):610-622.
4. Vidailhet M et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med. 2005;352(5):459-467.
5. Elias WJ et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2016;375(8):730-739.